Ameritas Investment Partners Inc. boosted its position in shares of First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report) by 5.5% during the first quarter, Holdings Channel.com reports. The fund owned 11,200 shares of the company’s stock after acquiring an additional 587 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in First Trust Nasdaq Pharmaceuticals ETF were worth $314,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Janney Montgomery Scott LLC bought a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF during the 1st quarter valued at $1,030,000.
First Trust Nasdaq Pharmaceuticals ETF Stock Performance
Shares of First Trust Nasdaq Pharmaceuticals ETF stock opened at $28.46 on Thursday. The company has a market capitalization of $18.50 million, a P/E ratio of 15.98 and a beta of 0.70. The company has a fifty day moving average of $27.25 and a 200 day moving average of $27.22. First Trust Nasdaq Pharmaceuticals ETF has a fifty-two week low of $23.85 and a fifty-two week high of $28.72.
First Trust Nasdaq Pharmaceuticals ETF Increases Dividend
About First Trust Nasdaq Pharmaceuticals ETF
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.
Recommended Stories
- Five stocks we like better than First Trust Nasdaq Pharmaceuticals ETF
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- Overbought Stocks Explained: Should You Trade Them?
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Earnings Season Sell-Off: Is This Tech Giant a Buy?
Want to see what other hedge funds are holding FTXH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report).
Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.